"Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. (Special issue: Drugs and COVID-19.)
Therapie
; 75(4):371-379, 2020.
Article
in English
| CAB Abstracts | ID: covidwho-1005755
ABSTRACT
Introduction:
COVID-19 is an unprecedented challenge for physicians and scientists. Several publicized drugs are being used with not much evidence of their efficacy such as hydroxychloroquine, azithromycin or lopinavir-ritonavir. Yet, the cardiac safety of these drugs in COVID-19 deserves scrutiny as they are known to foster cardiac adverse ADRs, notably QTc interval prolongation on the electrocardiogram and its arrhythmogenic consequences.
Full text:
Available
Collection:
Databases of international organizations
Database:
CAB Abstracts
Type of study:
Observational study
Language:
English
Journal:
Therapie
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS